Crispr Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Crispr Therapeutics (NASDAQ:CRSP) posted its quarterly earnings data on Monday, April 29th. The company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.03), Briefing.com reports. Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.50 million. During the same quarter in the prior year, the business earned ($0.62) EPS. Crispr Therapeutics’s revenue was down 78.6% compared to the same quarter last year.

Crispr Therapeutics stock traded down $0.61 during mid-day trading on Wednesday, hitting $38.82. The company’s stock had a trading volume of 308,400 shares, compared to its average volume of 702,883. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -11.28 and a beta of 3.11.

A number of research analysts recently commented on the stock. BidaskClub lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, April 29th. Goldman Sachs Group lowered shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $78.00 to $40.00 in a research report on Monday, January 28th. William Blair assumed coverage on shares of Crispr Therapeutics in a research report on Wednesday, March 13th. They issued a “market perform” rating on the stock. Finally, BTIG Research assumed coverage on shares of Crispr Therapeutics in a research report on Thursday, February 7th. They issued a “buy” rating and a $43.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $47.64.

In related news, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $42.03, for a total value of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares of the company’s stock, valued at approximately $7,840,360.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.40, for a total transaction of $3,442,888.00. Following the completion of the transaction, the president now directly owns 1,024,534 shares of the company’s stock, valued at approximately $41,391,173.60. The disclosure for this sale can be found here. Insiders sold a total of 128,693 shares of company stock valued at $5,222,495 in the last ninety days. Company insiders own 37.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Crispr Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS” was published by Mayfield Recorder and is the sole property of of Mayfield Recorder. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://mayfieldrecorder.com/2019/05/22/crispr-therapeutics-crsp-announces-earnings-results-misses-estimates-by-0-03-eps.html.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: What does a bar chart mean for investors?

Earnings History for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.